Top

Published in:

01-02-2012 | PRECLINICAL STUDIES

Cytotoxic activity of the titanium alkoxide (OPy)₂Ti(4AP)₂ against cancer colony forming cells

Authors: Elizabeth A. Williamson, Timothy J. Boyle, Rebecca Raymond, Jacqueline Farrington, Claire Verschraegen, Montaser Shaheen, Robert Hromas

Published in: Investigational New Drugs | Issue 1/2012

Summary

A novel family of titanium alkoxides with two stable pyridinemethoxide moieties bound to a titanium metal center were synthesized and tested for cytotoxic activity on a variety of cancer cell lines using colony formation assays. One compound, (OPy)₂Ti(4AP)₂, where OPy is NC₅H₅CH₂O⁻, and 4AP is 4-aminophenoxide (⁻OC₆H₅(NH₂)-4), demonstrated increased cytotoxicity in breast, colon, and pancreatic cancer cell lines at 100 nanomolar levels with only short exposures. Further, (OPy)₂Ti(4AP)₂ had activity in colon and pancreatic cancer cell lines that are usually resistant to chemotherapy. This demonstrates that these titanium compounds may have a role in anti-cancer therapy, similar to platinum-based compounds, and the (OPy)₂Ti(4AP)₂ compound specifically deserves further investigation as an anti-cancer agent in chemo-resistant solid tumors.

Wohl D, Canetta R (1998) Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 34:1522–1534CrossRef

Desoize B, Madoulet C (2002) Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 42:317–325PubMedCrossRef

Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Clin Cancer Res 13:4960–4963PubMedCrossRef

Caruso F, Rossi M (2004) Antitumor titanium compounds. Mini Rev Med Chem 4:49–60PubMedCrossRef

Harding MM, Mokdsi G (2000) Antitumour metallocenes: structure-activity studies and interactions with biomolecules. Curr Med Chem 7:1289–1303PubMed

Korfel A, Scheulen ME, Schmoll HJ, Gründel O, Harstrick A, Knoche M, Fels LM, Skorzec M, Bach F, Baumgart J, Sass G, Seeber S, Thiel E, Berdel WE (1998) Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors. Clin Cancer Res 4:2701–2708PubMed

Christodoulou CV, Ferry DR, Fyfe DW, Young A, Doran J, Sheehan TM, Eliopoulos A, Hale K, Baumgart J, Sass G, Kerr DJ (1998) Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer. J Clin Oncol 16:2761–2769PubMed

Christodoulou CV, Eliopoulos AG, Young LS, Hodgkins L, Ferry DR, Kerr DJ (1998) Anti-proliferative activity and mechanism of action of titanocene dichloride. Br J Cancer 77:2088–2097PubMedCrossRef

Frühauf S, Zeller WJ (1991) New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells. Cancer Res 51:2943–2948PubMed

10.

Boyle TJ, Sewell RM, Ottley LA, Pratt HD 3rd, Quintana CJ, Bunge SD (2007) Controlled synthesis of a structurally characterized family of sterically constrained heterocyclic alkoxy-modified titanium alkoxides. Inorg Chem 46:1825–35PubMedCrossRef

11.

Boyle TJ, Ottley LA, Rodriguez MA, Sewell RM, Alam TM, McIntyre SK (2008) Stepwise modification of titanium alkoxy chloride compounds by pyridine carbinol. Inorg Chem 47:10708–10717PubMedCrossRef

12.

Lee SH, Oshige M, Durant ST, Rasila KK, Williamson EA, Ramsey H, Kwan L, Nickoloff JA, Hromas R (2005) The SET domain protein Metnase mediates foreign DNA integration and links integration to nonhomologous end-joining repair. Proc Natl Acad Sci U S A 102:18075–18080PubMedCrossRef

13.

Wray J, Williamson EA, Royce M, Shaheen M, Beck BD, Lee SH, Nickoloff JA, Hromas R (2009) Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells. PLoS One 4:e5323PubMedCrossRef

14.

Fillmore CM, Kuperwasser C (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10:R25PubMedCrossRef

15.

Stathis A, Moore MJ (2010) Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7:163–172PubMedCrossRef

16.

Legoffic A, Calvo EL, Barthet M, Delpero JR, Dagorn JC, Iovanna JL (2009) Identification of genomic alterations associated with the aggressiveness of pancreatic cancer using an ultra-high-resolution CGH array. Pancreatology 9:267–272PubMedCrossRef

17.

Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R (2000) Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60:6039–6044PubMed

18.

van Rensburg CE, Joone GK, O’Sullivan JF (2000) Clofazimine and B4121 sensitize an intrinsically resistant human colon cancer cell line to P-glycoprotein substrates. Oncol Rep 7:193–195PubMed

19.

Kadota M, Yang HH, Gomez B, Sato M, Clifford RJ, Meerzaman D, Dunn BK, Wakefield LM, Lee MP (2010) Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS One 15:e9201CrossRef

20.

Parker Siburt CJ, Lin EM, Brandt SJ, Tinoco AD, Valentine AM, Crumbliss AL (2010) Redox potentials of Ti(IV) and Fe(III) complexes provide insights into titanium biodistribution mechanisms. J Inorg Biochem Apr 18 [epub ahead of print]

21.

Buck DP, Abeysinghe PM, Cullinane C, Day AI, Collins JG, Harding MM (2008) Inclusion complexes of the antitumour metallocenes Cp(2)MCl(2) (M = Mo, Ti) with cucurbit[n]urils. Dalton Trans 17:2328–2334PubMedCrossRef

22.

Gao LM, Matta J, Rheingold AL, Meléndez E (2009) Synthesis, structure and biological activity of amide-functionalized titanocenyls: improving their cytotoxic properties. J Organomet Chem 694:4134–4139PubMedCrossRef

23.

Kelter G, Sweeney NJ, Strohfeldt K, Fiebig HH, Tacke M (2005) In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes. Anticancer Drugs 16:1091–1098PubMedCrossRef

Title: Cytotoxic activity of the titanium alkoxide (OPy)2Ti(4AP)2 against cancer colony forming cells
Authors: Elizabeth A. Williamson
Timothy J. Boyle
Rebecca Raymond
Jacqueline Farrington
Claire Verschraegen
Montaser Shaheen
Robert Hromas
Publication date: 01-02-2012
Publisher: Springer US
Published in: Investigational New Drugs / Issue 1/2012
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-010-9530-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 1/2012

A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma

Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs

An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma

Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer

Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer

A Comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer